Long‐term remission after cessation of interferon‐α treatment in patients with severe uveitis due to Behçet's disease
Open Access
- 31 August 2010
- journal article
- vasculitis
- Published by Wiley in Arthritis & Rheumatism
- Vol. 62 (9) , 2796-2805
Abstract
Objective: To retrospectively assess the development of visual acuity and the frequency and duration of relapse‐free periods in patients who were treated with interferon‐α (IFNα) for severe uveitis due to Behçet's disease (BD) and who completed a followup period of ≥2 years.Methods: IFN alfa‐2a was administered at an initial dosage of 6 million IU per day, then tapered to a maintenance dosage of 3 million IU twice per week, and finally discontinued, if possible. In case of a relapse, IFN treatment was repeated. Visual acuity at the end of followup was compared with visual acuity when ocular disease was in remission.Results: Of 53 patients (96 eyes), 52 (98.1%) responded to IFN. In 47 patients (88.7%), IFN could be discontinued when the disease was in remission. Twenty of these 47 (42.6%) needed a second treatment course during a median followup of 6.0 years (range 2.0–12.6 years). Visual acuity improved or remained unchanged in 91 eyes (94.8%). Ocular disease was still in remission in 50% of the patients 45.9 months after cessation of the first IFN course. The relapse rate tended to be lower in women than in men. The BD activity score decreased significantly during followup, but long‐term remission of nonocular BD manifestations was not achieved. However, since local treatments were sufficient, no systemic treatment was administered.Conclusion: Our findings indicate that IFNα induces long‐lasting remission in patients with severe ocular BD, resulting in a notable improvement in visual prognosis.Keywords
This publication has 29 references indexed in Scilit:
- Interdisciplinary management recommendations for toxicity associated with interferon‐alfa therapyJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2008
- Behçet's disease: Ocular effects and treatmentProgress in Retinal and Eye Research, 2008
- Systematic review of ethnic variation in the phenotype of Behcet's diseaseScandinavian Journal of Rheumatology, 2007
- Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patientsBritish Journal of Ophthalmology, 2006
- The Long-Term Mortality and Morbidity of Behçet SyndromeMedicine, 2003
- Morbus Behçet: Uveitis-Therapie mit Interferon α2a - prospektive klinische (Pilot-)Studie an 33 Patienten1Klinische Monatsblätter für Augenheilkunde, 2001
- Efficacy and safety of systemic recombinant interferon‐alpha in Behcet's diseaseJournal of Internal Medicine, 1998
- Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot studyBritish Journal of Ophthalmology, 1998
- Treatment and visual prognosis in Behcet's disease.British Journal of Ophthalmology, 1986
- Renal Histopathologic Alterations in Patients Treated with Cyclosporine for UveitisNew England Journal of Medicine, 1986